RO7268489

Phase 2Small molecule

Roche

RO7268489 is one of 32 small molecule programs targeting Multiple Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

Progressive Multiple SclerosisRecruiting

Multiple SclerosisPhase 2

Active, not recruiting

Progressive Multiple SclerosisPhase 2

Recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Betaseron

Bayer

Preclinical

16 2

Kesimpta

Novartis

Preclinical

15 3

Tysabri

Biogen

Preclinical

14 4

Avonex

EMD Serono

Preclinical

22 5

Campath

GGenzyme, a Sanofi Company

Preclinical

12 6

Zinbryta

Roche

Preclinical

2 7

Flomax

Sanofi

Preclinical

1 8

Myfortic

Novantrone

Pred Forte

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Progressive Multiple Sclerosis

NCT07282574

Clinical

Trials by Indication[1]

Progressive Multiple Sclerosis1 trial

A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis

Recruiting· Roche logo

Roche·Phase 2·NCT07282574·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RO7268489. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO7268489 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO7268489. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

RO7268489

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Progressive Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News